Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC.
J Cancer Res Clin Oncol
; 149(17): 16055-16067, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37695389
ABSTRACT
PURPOSE:
Glioblastoma is one of the malignant tumors with poor prognosis and no effective treatment is available at present.METHODS:
To study the effect of cordycepin combined with temozolomide on glioblastoma, we explored the effect of the combination based on network pharmacology and biological verification.RESULTS:
It was found that the drug combination significantly inhibited the cell growth, proliferation, migration and invasion of LN-229 cells. Drug combination inhibited epithelial-mesenchymal transition (EMT) by up-regulating the expression of E-cadherin and suppressing the expression of N-cadherin, Zeb1 and Twist1. Through network pharmacology, we further explored the molecular mechanism of drug combination against glioblastoma, and 36 drug-disease common targets were screened. The GO biological process analysis included 44 items (P < 0.01), which mainly involved the regulation of apoptosis, cell proliferation, cell migration, etc. The enrichment analysis of KEGG pathways included 28 pathways (P < 0.05), and the first four pathways were "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway". We detected the expression of important genes in the pathways and PPI network, and the results showed that the drug combination down-regulated NFKB1, MYC, MMP-9, MCL1, CTNNB1, and up-regulated PDCD4.CONCLUSION:
Cordycepin combined with temozolomide may down-regulate MYC through "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway", which in turn regulate the expression of MCL1, CTNNB1, MMP9, PDCD4, thus regulating cell proliferation, migration and apoptosis in glioblastoma.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Glioblastoma
/
MicroRNAs
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Year:
2023
Type:
Article